Lung cancer (non-small cell)
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Where to go
1 hospital in India taking patients for this trial.
Registry summary (technical)
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.
Sponsor: Tata Memorial Hospital
NCT05236946 on ClinicalTrials.gov
Last updated on the registry 10 Sep 2025 · read by us 20 Oct 2026